Search by Year
26 Oct 2023
bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the nine months ended September 30, 2023. Consolidated sales amounted to €2,668 million for the first nine months of 2023.
19 Oct 2023
Oxford Nanopore Technologies plc (LSE: ONT) (“Oxford Nanopore”), the company delivering a new generation of nanopore-based molecular sensing technology, and bioMérieux SA, a world leader in the field of in vitro diagnostics (“IVD”) today announce that bioMérieux is making an immediate £70M investment in Oxford Nanopore.
13 Oct 2023
bioMérieux, a world leader in the field of in vitro diagnostics, announces the CE-marking of VIDAS® TBI (GFAP, UCH-L1), a blood test to support assessment of patients with mild traumatic brain injury (mTBI), based on a unique combination of brain biomarkers: GFAP and UCH-L1*.
11 Oct 2023
On October 11, 2023, the REVIDA Industrial Chair for Respiratory Infectious Diseases, led by researcher Sophie Trouillet-Assant (UCBL / HCL), was officially launched by Claude Bernard Lyon 1 University, Hospices Civils de Lyon, and bioMérieux, with the support of the Agence nationale de la recherche (National research agency, in France).
22 Sep 2023
bioMérieux submits Dual 510(k) and CLIA-waiver application to FDA for the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel
bioMérieux, a world leader in the field of in vitro diagnostics, has submitted the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel to U.S. Food and Drug Administration (FDA) for a dual 510(k) clearance and CLIA1-waiver. This panel is already CE-marked (IVDD).
01 Sep 2023
Consolidated sales amounted to €1,770 million in first-half 2023, a robust growth like-for-like of 8.3% from €1,658 million in the prior year.
26 Jul 2023
bioMérieux was recently awarded nine IMV ServiceTrak™ Clinical Laboratory Awards in the categories of Immunoassay, ID/AST, and Blood Culture excellence.
27 Jun 2023
Marcy-l’Étoile, France – June 27th, 2023. bioMérieux, a world leader in the field of in vitro diagnostics, announces the appointment of Jennifer Zinn as Executive Vice President of Clinical Operations...
14 Jun 2023
Marcy l’Étoile, France, June 14th, 2023 – bioMérieux, a world leader in the field of in vitro diagnostics, announces an evolution in its corporate governance. As of July 1st, 2023, Alexandre Mérieux w...
09 May 2023
Marcy-l’Étoile (France), May 9th, 2023 – bioMérieux, a world leader in the field of in vitro diagnostics, has received U.S. Food and Drug Administration (FDA) Clinical Laboratory Improvement Amendment...